Evidence Review

NMN (Nicotinamide Mononucleotide)

Verdict
Unproven
Evidence Tier
C
Weak evidence
Human Studies
Yes — limited
Typical Cost
$40-80/mo
NMN reliably increases NAD+ blood levels in human studies. However, no human trial has demonstrated improvements in hard clinical endpoints — lifespan extension, cardiovascular event reduction, or cancer prevention. The $1.2 billion NAD+ supplement market is built almost entirely on preclinical data and biomarker changes that may or may not translate to meaningful health outcomes.

The full evidence review — including which specific human endpoints have been measured and why the mouse-to-human translation is weaker than you think — is in Section 2 (Supplements & Compounds) of The Anti-Longevity Playbook.

Reviewed by Dr. Ramy Khalil, MD · Double Board-Certified Internal Medicine · Last updated March 2026

Does NMN work for longevity?

NMN reliably increases NAD+ blood levels, but no human trial has shown improvements in hard clinical endpoints like lifespan or cardiovascular events. The $1.2B market is built on preclinical data.

Free Chapter

Want the full picture?
Start with a free chapter.

Read the first chapter of The Anti-Longevity Playbook free — including the intervention with stronger mortality data than NMN.

No spam. Just the free chapter.